Peer Review History
Original SubmissionSeptember 30, 2019 |
---|
PONE-D-19-27407 Adherence to antiretroviral therapy and associated factors among HIV positive adults attending treatment at Nekemte referral hospital, west Ethiopia, 2019. PLOS ONE Dear Dr Muktar Abadiga, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== Specifically, one of the two reviewers raised very important points which merit to be considered prior to consideration for publication. ============================== We would appreciate receiving your revised manuscript by Jan 25 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Joseph Fokam, Ph.D Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed and/or translated a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. 3. We noticed you have some minor occurrence(s) of overlapping text with the following previous publication(s), which needs to be addressed: https://doi.org/10.1186/s13104-019-4553-0 https://doi.org/10.1186/s12879-018-3176-8 In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the Methods section. Further consideration is dependent on these concerns being addressed. 4. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate "supporting information" files. 5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Background 1 Inclusion of a brief description of key elements of ART services offered at the hospital can make reader understand the context better. Sample size determination and sampling techniques 1. Brief description of the sampling method would help reader to understand and determine if there were on potential sources of bias that can affect results and interpretation. What was the sampling framework – ART records at the facility or patients were randomly selected as they came for their clinic visit during the study month? 2. 311 patients should be estimated sample size for the study 3. It is not clear if 311 patients represent total number of patients at the facility, in the study design and setting section, “All ART patients on treatment follow up at Nekemte referral hospital was the source population and the sampled ART patients who had treatment follow up during the study period was the study population”, It would be easy to follow the sampling methodology if total number of patients on ART is mentioned and how random sampling was applied. Ethical consideration “Filled out questionnaires were carefully handled and all access to results was kept strictly within the author” brief description how records were handled and stored can help the leader to understand instead of just “carefully handle and kept strictly by author” Results 311 sampled - state out of how many patients in total. How were social support categories derived? What substances were used? WHO clinical staging and CD 4 count levels- explain when these were determined for the patients as they are likely to be influenced by ART. It is not clear if this was the patient’s status at the time of the study or at the time of the ART initiation. Or how recent? General comment: the author should ensure the grammatical errors are corrected throughout the manuscript. Reviewer #2: Review of PONE-D-19-27407 : “Adherence to antiretroviral therapy and associated factors among HIV positive adultsattending treatment at Nekemte referral hospital, west Ethiopia, 2019” for PLoS one General comments The author addresses a very important public health problem. As already stated by the author, ART adherence is a determining factor as far as the fight towards rolling-back the HIV/AIDS pandemic is concern. In this write-up, the author tries to determine the adherence status of patients on HAART and goes further to identify factors influencing adherence. The write-up is complete with all the required sections but still has some faults. The English in the whole write-up needs to be carefully corrected by a native English speaker or an expert. Some vital information is missing in the background and methodology section. In addition more clarifications are needed in some sections. Title: Please do replace the word “attending” with “accessing” Abstract 1. Please have your abstract read by a native English speaker and correct the errors 2. Please do precise in what direction each of the cited factors affects adherence to treatment. 3. What does the author mean by WHO standard? Please change “WHO standard” to “WHO recommendation”. Background The background encloses a lot of grammatical errors that need to be addressed carefully. Practically every sentence needs an English correction that I can’t go citing one after the other. This section is poorly organized with a lot of repetitions. I think in this section, the reader will want to know what ART is, and the importance of this treatment, what ART adherence is, current global findings on the status of adherence globally, in Africa and more specifically Ethiopia, what are the consequences of poor ART adherence and the impeding impact on the triple 90 ambitions set by the WHO, what are some of the factors registered in studies to influence ART adherence? And then you end with a paragraph on why the present study was necessary. Please do reorganize this section accordingly. 4. In the last paragraph of your background. “Since most of the Ethiopian setting is resource limited, there are no routine assessments for ART adherence among PLHIV in Ethiopia”. I don’t see any cause effect relationship in the two parts of this statement. In addition, I think in all HIV treatment centers routine follow-up ART adherence is done at the level of the center. 5. The fact that studies are few does not justify your work. Studies might be few but present enough evidence in that domain. I think that with changes in HIV related strategies, changes in the sociodemographic and economic status, with the routine interventions to combat HIV related stigma and discrimination, with the recent adoption of the test-and-treat strategy……etc, evaluative studies to mark progress on the status of ART adherence and possible associated factors (which might have changed over time) are necessary. 6. Please also do reformulate with more precision the objective of this study presented at the end of this section. Please end with a full stop. Methods This section lacks some very important precisions and the English errors persist. 7. Nekemte referral hospital. Nothing is said on the treatment center in this hospital. What rational have you for choosing this hospital for your study? How many patients does this center follow up monthly? How many workers found in the center and what are their qualifications? Are all these workers trained? 8. Refusal to participate is an ethical issue and not an exclusion criteria. In addition, were newly diagnosed patients included? What about those who arrived critically ill? 9. How were participants included in this study? I guess that data collectors were stationed at the treatment center. How was your simple random sampling implemented? 10. Were the data collectors workers at the HIV unit? Or did they come to the unit just to do data collection? How were potential eligible participants identified? What strategies were used to reduce stigmatization associated to the new team if they were new? 11. The design used in this study is disturbing except clarifications will come. Were blood samples of the participants collected for work ups (case of CD4 for instance) or was there any documentary or register review? If all was done by interview, how did you verify the information? 12. The procedure of implementation and the data collection procedure is scanty. Were any administrative procedures undertaken? How did data collectors approach eligible participants? Were interviews done behind closed doors? etc 13. The data processing and analysis section is very scanty and cannot be reproduced. The result section presents two p-values….0.25 and 0.05 for which this is not mentioned in this section. How were variables included into the multivariable regression analysis? 14. The data control section logically should be presented before analysis. In addition what was the content of the one day training delivered to data collectors and supervisors? Were supervisors and data collectors given the same training? 15. Clearly state in the ethical consideration section. What type of consent was obtained from participants. 16. The data collection tool should be made available for publication to ease reproducibility. Results Please do correct the English in this section. In general, the confidence intervals of the odd ratios are very large indicative of small cell number as far as the considered variables are concerned. 17. Looking at your age distribution, it seems skewed and therefore the best measure of central tendency is the median. 18. How did you clinically stage your participants only by interview? 19. How did you measure knowledge on HIV and treatment. Please clearly state how this was done on the methods section. Who had good knowledge and who poor knowledge? 20. The variable on social support is vague and undefined in methods. Social support from who? Family, friends, or personnel?. Considering that true social support can only be evaluated in case of disclosure of status. Reported information should be very precise 21. Another problem is what you called adverse drug reaction in your questionnaire. Please precise and clearly define all these variables in the methods section. 22. The adherence status in this study is a very important proportion in this study. Please do present this proportion with its 95% confidence interval. In addition, it would be more light to present those with adherence evaluated to be between below 70%, between 70-80%, 80-90%, 90-95%....before those evaluated above 95%. This will help the reader understand the relative adherence level of the treated population. Discussion The English needs strengthening. This section is short and really does not put to context the findings in this research. The authors spend time comparing their findings on the ART adherence status to those in other studies and fail to discuss the true meaning and implication of their results. Some of the factors are addressed and others no, what criteria did the author use in choosing which factors to discuss and which not to. Discrepancies are not really well justified Conclusion Please reformulate the sentences and correct the English errors Tables The results on the tables are well presented and can be followed but these statistical analyses are not well described in the data analysis section. Please correct accordingly. Also define abbreviations like COR,AOR, CI below your tables. Data availability statement is missing. The author should provide the data sets analysed for the above findings. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: ATEM Bethel Ajong [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.
|
Revision 1 |
PONE-D-19-27407R1 Adherence to antiretroviral therapy and associated factors among Human immunodeficiency virus positive patients accessing treatment at Nekemte referral hospital, west Ethiopia, 2019. PLOS ONE Dear Mr Abadiga, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by May 24 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, M Barton Laws Academic Editor PLOS ONE Additional Editor Comments (if provided): You have responded to most of the reviewers' comments. However, I must ask you to address some important issues of presentation. The English is comprehensible but there are still a number of grammatical errors and odd word choices. It would be in your interest to have it very carefully proofread and copy edited by someone with native English fluency. the background section is highly repetitive. You make the same statements multiple times, in several different ways. It could easily be 1/4 as long. At Line 152 you do not need to give the response rate here. You give it in the results, which is appropriate. You need to provide references for the Oslo Social Support Scale and the HIV stigma scale Line 210 It is SPSS Windows, not window. The publisher of the software should be provided in parentheses. Line 261 "The minimum age of the study participants was 18 years and maximum age was 56 years. Therefore, the median age of the study participant was 31.00 years with a range of 38 263 years (56 years-18 years)." Again, this is repetitive. Please review the manuscript carefully for redundancy and express yourselves concisely. Line 316. P values of 0.25 are not considered significant. Conventionally, a p value of >.05 is considered the threshold for significance; even so you should point out that you are making multiple comparisons so some of these associations may be spurious. Please remove the asterisks from all values higher than .05. Line 329: "Strong family/social support were 6.21 times more likely to adhere to their medication than those who had poor family/social support (Adjusted odd ratio= 6.21, 95% Confidence interval: 1.39, 27.62)". This is not the meaning of an odds ratio. Please simply say "People with strong family social support were more likely to adhere to their medication than those with poor family/social support (AOR = 6.21, C.onfidence interval: 1.39, 27.62) Remove all references to likelihood ratios. Table 4: You should run and present a parsimonious model without the non-significant variables. If you can respond to these comments I may not need to send this out again for peer review, but I do not want to burden reviewers with making these points. I know you want to make a good presentation of your work. I believe this is informative and can usefully guide clinical care, but it has to be readable and properly presented. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: No ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: RE-REVIEW of “Adherence to antiretroviral therapy and associated factors among Humanimmunodeficiency virus positive patients accessing treatment at Nekemte referral hospital, west Ethiopia, 2019” I wish to thank the author for the point by point rebuttal to the comments brought up in the last review. I appreciate the commitment of the author in addressing each of the reviewers’ comments. I am satisfied with most of the explanations given for my questions and modifications done. I am however sorry that the manuscript in its present condition does not meet all publication criteria for PLOS one. The article is not presented in an intelligible fashion nor is it written in standard English. The message can be very good but the written communication handicaps everything. It is disturbing that grammatical errors persist in the manuscript right from the first statement of the introduction. I beg to differ with the author; no strengthening of the English in the write up was done. It is not the place of the reviewer to correct the English in a manuscript but from evaluation of the language strength in this scientific write up, I think it hides the scientific message the author is trying to pass. That said, I suggest the author contacts an expert to edit the English in this manuscript while he addresses these additional comments. 1. Take off the full stop from your title. 2. The authors in their background still neglect a key public health goal (the triple 90 ambition by 2020) which is threatened by non-adherence. According to this ambition, 90 percent of all people receiving ART will have viral suppression by 2020. Some of the paragraphs in your background are just a repetition of the same thing in other words. Your data was collected in 2019, a paragraph should present this and I think bringing it up in the discussion of the results is also key. 3. The author states in the last paragraph of background “It is essential to assess the number of people living with HIV/AIDS drop out of treatment programmes and factors affecting adherence to ART”. The reason they state is because of few studies…. And he moves on to give the goal of the study. My question is why Nekemte? And why now? What is the difference in the population constitution between other places in Ethiopia and Nekemte which you think could affect their behaviours and therefore adherence? In the last review, I gave you a direction of thinking to clearly justify your research in that place. 4. Please present the study design before the setting of your study. 5. The author states that a simple random sampling method was adopted (by lottery) to included participants in the study. How was this done? Was it done using the patient files? Or how was it done given that patients on follow-up do not visit the facility all at once? I ask this question because I want to be sure each of the 2251 patients followed up in the facility by your random sampling had equal chances of being included in your study. 6. The additional information added on the sample size section is problematic. First of all, the author does not state why he excluded six participants. Secondly, given that a non-response rate of 5% was considered in building up that sample size, a shortage of six participants is not a problem given that 5% of that sample is 15. I suggest you just take that addition off. 7. Include the place of 0.25 in the data analysis section. 8. The limits of the study should emanate from structured discussions and should be presented before the conclusions because conclusions take note of the limits of the results. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: Yes: ATEM BETHEL AJONG [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 2 |
PONE-D-19-27407R2 Adherence to antiretroviral therapy and associated factors among Human immunodeficiency virus positive patients accessing treatment at Nekemte referral hospital, west Ethiopia, 2019. PLOS ONE Dear Mr Abadiga, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by May 31 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, M Barton Laws Academic Editor PLOS ONE Additional Editor Comments (if provided): You have responded to the reviewer's comments and to mine. I must tell you that while the quality of English is much improved, there are occasional infelicities. These do not harm the readability of the paper so I leave it to you whether to do another round of copy editing. While I do not feel this needs to be sent out for further review, there are two issues I ask you to address. At Line 84: "Literature showed that above 95% adherence to the therapeutic regimen is required for HIV infected patients to reach full viral suppression [13-16]. The level of adherence to ART is 85.5% in China [17], 84.0% in Myanmar [18], 71.0% in Northern Tanzania [19] 87 and 62.2% in Ghana [20]. In Ethiopia, the rate of adherence to antiretroviral therapy is 88.2% [21]." I believe you are confusing two different ideas. In the first sentence, you are referring to the percentage of doses and individual patient takes as prescribed. In the following sentences, it appears you are referring to the percentage of patients who meet this standard. You should clarify this difference. At line 139: "The sample size was calculated using the formula for estimation of a single population proportion with the assumptions of 95 % Confidence Level (CL) and marginal error (d) of 0.05. An adherence level of 0.74 (74.0 %) was taken from the study conducted inAddis Ababa [27]. After adding a non-response rate of 5%, a total of 311 ART patients were enrolled in the study." You do not state the result of this power calculation. If you can clarify these issues I believe the paper will be suitable for publication. [Note: HTML markup is below. Please do not edit.] [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 3 |
Adherence to antiretroviral therapy and associated factors among Human immunodeficiency virus positive patients accessing treatment at Nekemte referral hospital, west Ethiopia, 2019. PONE-D-19-27407R3 Dear Dr. Abadiga, We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, M Barton Laws Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
Formally Accepted |
PONE-D-19-27407R3 Adherence to antiretroviral therapy and associated factors among Human immunodeficiency virus positive patients accessing treatment at Nekemte referral hospital, west Ethiopia, 2019. Dear Dr. Abadiga: I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. For any other questions or concerns, please email plosone@plos.org. Thank you for submitting your work to PLOS ONE. With kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. M Barton Laws Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .